Skip to main content
. Author manuscript; available in PMC: 2022 Mar 17.
Published in final edited form as: Leukemia. 2021 Oct 21;36(3):781–789. doi: 10.1038/s41375-021-01444-6

Figure 4. TP53 status differentiates patients in the clinically defined high-risk group in paediatric B-NHL.

Figure 4

Kaplan-Meier plots showing (A) progression-free and (B) overall survival for high, intermediate and low clinical risk groups, and (C) progression-free and (D) overall survival in high-risk patients according to the presence of any TP53 abnormality.